All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Sattva Neelapu, MD Anderson Cancer Center, Houston, US, about the ZUMA-12 study. We asked, Is chimeric antigen receptor T-cell therapy effective in high-risk diffuse large B-cell lymphoma (DLBCL) as first-line therapy?
ZUMA-12: Is CAR T-cell therapy effective in high-risk DLBCL as first-line therapy?
Neelapu reports the promising results from the interim analysis of the phase II ZUMA-12 study, evaluating axicabtagene ciloleucel as first-line therapy in patients with high-risk DLBCL.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox